A Fully Implantable Wireless ECoG 128-Channel Recording Device for Human Brain–Machine Interfaces: W-HERBS

Brain–machine interfaces (BMIs) are promising devices that can be used as neuroprostheses by severely disabled individuals. Brain surface electroencephalograms (electrocorticograms, ECoGs) can provide input signals that can then be decoded to enable communication with others and to control intelligent prostheses and home electronics. However, conventional systems use wired ECoG recordings. Therefore, the development of wireless systems for clinical ECoG BMIs is a major goal in the field. We developed a fully implantable ECoG signal recording device for human ECoG BMI, i.e., a wireless human ECoG-based real-time BMI system (W-HERBS). In this system, three-dimensional (3D) high-density subdural multiple electrodes are fitted to the brain surface and ECoG measurement units record 128-channel (ch) ECoG signals at a sampling rate of 1 kHz. The units transfer data to the data and power management unit implanted subcutaneously in the abdomen through a subcutaneous stretchable spiral cable. The data and power management unit then communicates with a workstation outside the body and wirelessly receives 400 mW of power from an external wireless transmitter. The workstation records and analyzes the received data in the frequency domain and controls external devices based on analyses. We investigated the performance of the proposed system. We were able to use W-HERBS to detect sine waves with a 4.8-μV amplitude and a 60–200-Hz bandwidth from the ECoG BMIs. W-HERBS is the first fully implantable ECoG-based BMI system with more than 100 ch. It is capable of recording 128-ch subdural ECoG signals with sufficient input-referred noise (3 μVrms) and with an acceptable time delay (250 ms). The system contributes to the clinical application of high-performance BMIs and to experimental brain research

Totally Implantable Bidirectional Neural Prostheses: A Flexible Platform for Innovation in Neuromodulation.

Implantable neural prostheses are in widespread use for treating a variety of brain disorders. Until recently, most implantable brain devices have been unidirectional, either delivering neurostimulation without brain sensing, or sensing brain activity to drive external effectors without a stimulation component. Further, many neural interfaces that incorporate a sensing function have relied on hardwired connections, such that subjects are tethered to external computers and cannot move freely. A new generation of neural prostheses has become available, that are both bidirectional (stimulate as well as record brain activity) and totally implantable (no externalized connections). These devices provide an opportunity for discovering the circuit basis for neuropsychiatric disorders, and to prototype personalized neuromodulation therapies that selectively interrupt neural activity underlying specific signs and symptoms

Bioresorbable silicon electronics for transient spatiotemporal mapping of electrical activity from the cerebral cortex.

Bioresorbable silicon electronics technology offers unprecedented opportunities to deploy advanced implantable monitoring systems that eliminate risks, cost and discomfort associated with surgical extraction. Applications include postoperative monitoring and transient physiologic recording after percutaneous or minimally invasive placement of vascular, cardiac, orthopaedic, neural or other devices. We present an embodiment of these materials in both passive and actively addressed arrays of bioresorbable silicon electrodes with multiplexing capabilities, which record in vivo electrophysiological signals from the cortical surface and the subgaleal space. The devices detect normal physiologic and epileptiform activity, both in acute and chronic recordings. Comparative studies show sensor performance comparable to standard clinical systems and reduced tissue reactivity relative to conventional clinical electrocorticography (ECoG) electrodes. This technology offers general applicability in neural interfaces, with additional potential utility in treatment of disorders where transient monitoring and modulation of physiologic function, implant integrity and tissue recovery or regeneration are required

A Wireless Neuroprosthesis for Patients with Drug-refractory Epilepsy:A Proof-of-Concept Study

Objective Acute or protracted cortical recording may be necessary for patients with drug-refractory epilepsy to identify the ictogenic regions before undergoing resection. Currently, these invasive recording techniques present certain limitations, one of which is the need for cables connecting the recording electrodes placed in the intracranial space with external devices displaying the recorded electrocorticographic signals. This equates to a direct connection between the sterile intracranial space with the non-sterile environment. Due to the increasing likelihood of infections with time, subdural grids are typically removed a few days after implantation, a limiting factor in localizing the epileptogenic zone if seizures are not frequent enough to be captured within this time-frame. Furthermore, patients are bound to stay in the hospital, connected by the wires to the recording device, thus increasing substantially the treatment costs. To address some of the current shortcomings of invasive monitoring, we developed a neuroprosthesis made of a subdural silicone grid connected to a wireless transmitter allowing prolonged electrocorticografic recording and direct cortical stimulation. This device consists of a silicone grid with 128-platinum/iridium contacts, connected to an implantable case providing wireless recording and stimulation. The case also houses a wirelessly rechargeable battery for chronic long-term implants. We report the results of the first human proof-of-concept trial for wireless transmission of electrocorticographic recordings using a device suited for long-term implantation in three patients with drug-refractory epilepsy. Methods Three patients with medically refractory epilepsy underwent the temporary intraoperative placement of the subdural grid connected to the wireless device for recording and transmission of electrocorticographic signals for a duration of five minutes before the conventional recording electrodes were placed or the ictal foci were resected. Results Wireless transmission of brain signals was successfully achieved. The wireless electrocorticographic signal was judged of excellent quality by a blinded neurophysiologist. Conclusions This preliminary experience reports the first successful placement of a wireless electrocorticographic recording device in humans. Long-term placement for prolonged wireless electrocorticographic recording in epilepsy patients will be the next step

Biointegrated and wirelessly powered implantable brain devices: a review

Implantable neural interfacing devices have added significantly to neural engineering by introducing the low-frequency oscillations of small populations of neurons known as local field potential as well as high-frequency action potentials of individual neurons. Regardless of the astounding progression as of late, conventional neural modulating system is still incapable to achieve the desired chronic in vivo implantation. The real constraint emerges from mechanical and physical diffierences between implants and brain tissue that initiates an inflammatory reaction and glial scar formation that reduces the recording and stimulation quality. Furthermore, traditional strategies consisting of rigid and tethered neural devices cause substantial tissue damage and impede the natural behaviour of an animal, thus hindering chronic in vivo measurements. Therefore, enabling fully implantable neural devices, requires biocompatibility, wireless power/data capability, biointegration using thin and flexible electronics, and chronic recording properties. This paper reviews biocompatibility and design approaches for developing biointegrated and wirelessly powered implantable neural devices in animals aimed at long-term neural interfacing and outlines current challenges toward developing the next generation of implantable neural devices

An Electrocorticographic Brain Interface in an Individual with Tetraplegia

Brain-computer interface (BCI) technology aims to help individuals with disability to control assistive devices and reanimate paralyzed limbs. Our study investigated the feasibility of an electrocorticography (ECoG)-based BCI system in an individual with tetraplegia caused by C4 level spinal cord injury. ECoG signals were recorded with a high-density 32-electrode grid over the hand and arm area of the left sensorimotor cortex. The participant was able to voluntarily activate his sensorimotor cortex using attempted movements, with distinct cortical activity patterns for different segments of the upper limb. Using only brain activity, the participant achieved robust control of 3D cursor movement. The ECoG grid was explanted 28 days post-implantation with no adverse effect. This study demonstrates that ECoG signals recorded from the sensorimotor cortex can be used for real-time device control in paralyzed individuals

Bionode5.0: A miniature, wireless, closed-loop biological implant for neuromodulation

The needs for electrotherapy, using electrical devices, are significantly increasing, due to limitations that pharmaceutical therapies may have, such as unignorable side effects and meager side effects on a multitude of cardiovascular and neurological diseases. To research on electrotherapy using an implantable electronic module, a miniature, wireless, and closed-loop implantable device, called Bionode , has been developed at Center for Implantable Device, directed by Dr. Pedro Irazoqui. Bionode4.1, the most recent version of the Bionode, is a device that consists of three different printed circuit boards(PCB), including a wireless communication system, an inductive power receiving system, and a two-channel recording system with a stimulator that has an ability to output a biphasic constant current stimulation. However, a few issues were brought to the surface during the fabrication process and in-vivo animal tests: 1) Unwanted data loss due to the failure of communication between the device and the Base Station, 2) stimulator\u27s imbalanced output with glitches and noise, 3) structural complexity that made debugging and constructing the device difficult, 4) device configuration, which could not be customized for the specific applications. These limitations found in Bionode 4.1 led to the development of the new version of Bionode, Bionode 5.0 . In order to increase the fidelity of the data transmission, a meandered inverted F trace antenna, which can cover the 2.4 GHz industrial, scientific, and medical (ISM) radio band, was designed and implemented in the wireless communication system of the Bionode 5.0. In order to resolve the stimulation issue, the old stimulator built in Bionode 4.1 was replaced with an upgraded stimulation circuitry that consists of the additional feedback system and the switches for suppressing the imbalanced pulses and controlling the unwanted glitches on the output. Re-optimizing the overall floor plan of the device and utilizing a new type of board-to-board connector solved the issues related to the structure and customizability. As a result, Bionode 5.0 with the smaller volume and the larger utilizable surface area resolved the issues that Binode4.1 had and would potentially allow the users to widely utilize the new version in various applications for the medical research

Optoelectronic Neural Implant Sensors for Cerebral Blood Volume Monitoring

Nearly 50 million people are afflicted with epilepsy, worldwide. These patients suffer from unprovoked seizures, where neurons in the cerebral cortex under go uncontrolled, hypersynchronous firing of neurons. 30\% of patients with epilepsy do not respond to drug treatments. For these patients, surgical treatment involving the removal or disconnection of brain matter is one of the only alternatives. Such surgical treatments often rely on long-term monitoring of neuronal activity in the brain using subdurally implanted surface electrodes to locate the epileptic focus, but these clinical methods for mapping neuronal activity suffer from low spatial resolutions and poor noise, which can limit the success of surgical treatments where an error of even 1 mm can be critical. The work described here involves the development of an implantable system for performing optical recordings of intrinsic signal (ORIS) on the surface of the brain. By taking advantage of the unique absorption spectrum of hemoglobin, cerebral blood volume (CBV) can be measured via reflectivity changes in the brain at at specific wavelengths of light. Due to the metabolic demands of the brain, the exaggerated neuronal activity and spiking associated with epileptic seizures can be detected indirectly through changes in CBV. While high resolution ORIS measurements have been recorded using externally mounted CCD sensors, this work presents some of the first developments in producing a fully implantable ORIS sensor. Progress in the development of an implantable ORIS sensor described here includes: an implantable organic light emitting diode (OLED) and organic photodetector (OPD) integrated on a highly flexible parylene-c substrate, an implantable sensor using a microLED array embedded on a flexible polyimide substrate, and the application of quantum dots to microLEDs for optical down-conversion. Successful in vivo detection of seizures is achieved with high signal-to-noise using these methods. Additionally, spatial localization of seizure activity is performed using the microLED array. These developments represent crucial first steps in the development of a full 2D neuronal mapping system using implantable ORIS devices